Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs

European Journal of Clinical Investigation

Volumn 39, Issue 3, 2009, Pages 174-182

  Pels, K ^a   Schwimmbeck, P L ^b   Rosenthal, P ^a   Loddenkemper, C ^a   Dang Heine, C ^a   Rauch, U ^a   Martens, H ^a,c   Schultheiss, H P ^a   Dechend, R ^a   Deiner, C ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KLINIKUM LEVERKUSEN   (Germany)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Clopidogrel; Drugs; Lesion; Platelets; Restenosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL WALL THICKNESS; ARTERY DIAMETER; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG INHIBITION; ELECTRON THERAPY; NONHUMAN; PRIORITY JOURNAL; SWINE; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT DURATION; TREATMENT RESPONSE;

ANIMALS; ASPIRIN; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; NF-KAPPA B; PLATELET AGGREGATION INHIBITORS; STATISTICS AS TOPIC; SUS SCROFA; TICLOPIDINE; TIME FACTORS; TRANSCRIPTION FACTOR AP-1;

EID: 61349148702     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02089.x     Document Type: Article

References (37)

1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. stent anticoagulation restenosis study investigators. N Engl J Med 1998 339 : 1665 71.
2. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000 102 : 624 9.
3. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C et al. Guidelines for percutaneous coronary interventions: the task force for percutaneous coronary interventions of the European society of cardiology. Eur Heart J 2005 26 : 804 47.
4. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005 31 : 174 83.
5. Quinn MJ, Bhatt DL, Zidar F, Vivekananthan D, Chew DP, Ellis SG et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004 93 : 679 84.
6. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006 24 : 33 50.
7. Steinhubl SR, Berger PB, Mann JT, 3rd, Fry ET, DeLago A, Wilmer C et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002 288 : 2411 20.
8. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005 366 : 1607 21.
9. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001 345 : 494 502.
10. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001 358 : 527 33.
11. Sabatine MS, Cannon CP, Gibson CM, Lopez-Sendon JL, Montalescot G, Theroux P et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005 294 : 1224 32.
12. Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006 354 : 1706 17.
13. GUSTO Investigators, An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993 329 : 673 82.
14. Deiner C, Loddenkemper C, Rauch U, Rosenthal P, Pauschinger M, Schwimmbeck PL et al. Mechanisms of late lumen loss after antiproliferative percutaneous coronary intervention using beta-irradiation in a porcine model of restenosis. Cardiovasc Revasc Med 2007 8 : 94 8.
15. Pels K, Deiner C, Coupland SE, Noutsias M, Sutter AP, Schultheiss HP et al. Effect of adventitial VEGF (165) gene transfer on vascular thickening after coronary artery balloon injury. Cardiovasc Res 2003 60 : 664 72.
16. Deiner C, Schwimmbeck PL, Koehler IS, Loddenkemper C, Noutsias M, Nikol S et al. Adventitial VEGF165 gene transfer prevents lumen loss through induction of positive arterial remodeling after PTCA in porcine coronary arteries. Atherosclerosis 2006 189 : 123 32.
17. Deiner C, Shagdarsuren E, Schwimmbeck PL, Rosenthal P, Loddenkemper C, Rauch U et al. NF-κB and AP-1 activation is associated with late lumen loss after porcine coronary angioplasty and antiproliferative beta-irradiation. Cardiovasc Res 2007 75 : 195 204.
18. Noutsias M, Pauschinger M, Schultheiss H, Kühl U. Phenotypic characterization of infiltrates in dilated cardiomyopathy - diagnostic significance of T-lymphocytes and macrophages in inflammatory cardiomyopathy. Med Sci Monit 2002 8 : CR478 87.
19. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A et al. NF-κB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000 35 : 193 201.
20. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997 9 : 240 6.
21. Barnes PJ, Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997 336 : 1066 71.
22. Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001 103 : 363 8.
23. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006 27 : 647 54.
24. Virmani R, Liistro F, Stankovic G, Di Mario C, Montorfano M, Farb A et al. Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans. Circulation 2002 106 : 2649 51.
25. Takeuchi K, Itoh H, Yonemitsu Y, Matsumoto T, Kume M, Komori K et al. In vivo reduction of the nuclear factor-κB activity using synthetic cis-element decoy oligonucleotides suppresses intimal hyperplasia in the injured carotid arteries in rabbits. Surg Today 2007 37 : 575 83.
26. Ohtani K, Egashira K, Nakano K, Zhao G, Funakoshi K, Ihara Y et al. Stent-based local delivery of nuclear factor-κB decoy attenuates in-stent restenosis in hypercholesterolemic rabbits. Circulation 2006 114 : 2773 9.
27. Murrell M, Khachigian L, Ward MR. The role of c-jun in PDTC-sensitive flow-dependent restenosis after angioplasty and stenting. Atherosclerosis 2007 194 : 364 71.
28. Ayral Y, Rauch U, Goldin-Lang P, Stellbaum C, Deiner C, Schwimmbeck PL et al. Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model. Cardiovasc Revasc Med 2007 8 : 183 8.
29. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J et al. Inflammatory response after intervention assessed by serial C-reactive protein measurements correlates with restenosis in patients treated with coronary stenting. Am Heart J 2005 150 : 344 50.
30. Kereiakes DJ. Adjunctive pharmacotherapy before percutaneous coronary intervention in non-ST-elevation acute coronary syndromes: the role of modulating inflammation. Circulation 2003 108 : III22 7.
31. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P et al. Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease. Diabetes 2006 55 : 780 4.
32. Koh TW. Long-term clopidogrel therapy in the drug-eluting stent era: beyond CREDO and PCI-CURE. Eur Heart J 2004 25 : 1364 author reply 5.
33. Anderson HV, McNatt J, Clubb FJ, Herman M, Maffrand JP, DeClerck F et al. Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries. Circulation 2001 104 : 2331 7.
34. Hart CE, Kraiss LW, Vergel S, Gilbertson D, Kenagy R, Kirkman T et al. PDGFbeta receptor blockade inhibits intimal hyperplasia in the baboon. Circulation 1999 99 : 564 9.
35. Le Breton H, Plow EF, Topol EJ. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol 1996 28 : 1643 51.
36. Crowley ST, Dempsey EC, Horwitz KB, Horwitz LD. Platelet-induced vascular smooth muscle cell proliferation is modulated by the growth amplification factors serotonin and adenosine diphosphate. Circulation 1994 90 : 1908 18.
37. Pakala R, Willerson JT, Benedict CR. Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 1997 96 : 2280 6.